Thermo Fisher Scentific

Thermo Fisher Scientific surged 8.71% to $572.32 by post-market close on July 24 Beijing time, powered by second-quarter earnings that significantly exceeded analyst expectations. Pre-market trading saw the stock jump from the prior close of $526.46 to $575.77, a gain exceeding 9%, reflecting strong market enthusiasm for the results; regular trading subsequently pulled back slightly but retained gains. Q2 revenue hit $11.99 billion, beating consensus, while adjusted earnings per share of $6.03 surpassed the estimate of $5.71, prompting management to raise full-year 2026 guidance and hike the dividend. Analyst Daniel Brennan raised the price target to $675, citing strengthening operational recovery and improving earnings power. The stock currently trades approximately 11% below its January 52-week high of $643.99 and remains down 3.41% year-to-date, relatively resilient amid sector headwinds. However, the current 31x P/E multiple reflects elevated valuation, pricing in substantial growth expectations.

Thermo Fisher navigated a volatile session driven by profit-taking, declining 1.66% intraday to $517.73 before recovering to close up 0.57% at $526.46, extending further into after-hours trading to $531.99. Despite near-term pullback pressure, the company's Q1 earnings supported the bull case: EPS of $4.43 rose 11.31% year-over-year and operating revenue of $11.01 billion grew 6.18%, marking solid execution in the life sciences sector. However, elevated valuation remains a consideration at 28.57x PE, and year-to-date performance has lagged with an 11.15% decline. The stock trades above both 20-day moving average ($520.07) and 60-day moving average ($484.42), though still 18.25% removed from the 52-week high of $643.99 reached in January. With a market capitalization of $195.6 billion, Morgan Stanley maintains a buy rating despite the near-term consolidation pressure.

TMO declined 4.22% in premarket trading, dragged down by sector headwinds following Danaher's revenue guidance cut, which pressured the diagnostics and biotech equipment space; however, the stock staged a robust intraday rebound, surging from a low of $498.78 (09:30 ET) to $523.46, recovering most losses and ending just 0.15% below yesterday's close. The recovery reflects sustained confidence in TMO's fundamentals — Morgan Stanley maintains a Buy rating. Q1 results showed EPS growth of 11.31% year-over-year and revenue growth of 6.18%, underscoring steady organic expansion. From a valuation standpoint, the current price of $523.46 is 11.65% below the year-to-date start of $592.51 and 18.72% below the 52-week high of $643.99, yet trades above both the 20-day moving average ($517.21) and 60-day moving average ($483.48), with a PE of 28.41 reflecting a reasonable premium befitting a quality blue-chip name.

TMO declined 1.2% to $526.23 today, with most weakness concentrated during regular trading hours where the stock fell from $531.15 (13:22 ET) to a session low of $523.23 (11:00 ET) before finishing at $526.23. The primary driver is subsidiary Devyser's Q2 results shock—EBIT plunged 90.91% and revenues fell 10.7%—raising investor concerns about contagion risk to the parent company. On TMO's own front, Q1 2026 earnings signal moderating momentum: revenue rose just 6.18% year-over-year, trailing Q4's 7.2% growth, while net margin compressed from 16.08% to 15.00%. Though EPS expanded 11.31% to $4.43, return on equity slid from 15.05% to 12.54%, signaling efficiency headwinds. Valuation-wise, the stock is down 18.29% from its 52-week high of $643.99 and has declined 11.19% year-to-date. Offsetting negatives, Morgan Stanley maintains a Buy rating, and the company announced a $0.47 quarterly dividend, indicating management confidence in cash generation.

TMO closed down approximately 1.5% today, primarily due to profit-taking pressure. The stock was relatively flat in pre-market trading but declined over 1.9% during regular hours before recovering slightly in post-market trading. Q1 2026 EPS of $4.43 rose 11.31% year-over-year, while operating revenue reached $11.01 billion, up 6.18% YoY, with net profit growth of 9.56%, reflecting steady earnings momentum. Recent developments include the launch of next-generation chimerism analysis assay, FDA approval for rapid DNA crime scene detection, and deepening mRNA manufacturing collaborations. From a valuation perspective, the stock has declined 10.13% year-to-date and trades 17.32% below its 52-week high of $643.99, though it remains above its 60-day moving average of $482.33. The P/E ratio of 28.9 suggests valuations remain at elevated levels, potentially limiting further upside.